FDA Grants Orphan Drug Designation to Gamgertamig for Pemphigus
LKFT sits 15% above its 52-week low of $25.68 on light trading volume (0.4× avg).
Summary
Lakefront Biotherapeutics announced FDA Orphan Drug Designation for gamgertamig in pemphigus, expanding the drug's regulatory footprint to a third autoimmune indication as Phase 1b trials continue enrolling globally.
Key Events · Product Development and Regulatory · LKFT
-
FDA Orphan Drug Designation for Pemphigus
The U.S. FDA granted Orphan Drug Designation to gamgertamig for the treatment of pemphigus, adding to prior Orphan and Fast Track designations in AIHA and ITP.
-
Regulatory Exclusivity and Commercial Protection
Orphan status provides seven years of U.S. market exclusivity upon approval, plus tax credits and fee waivers, strengthening the commercial case for the pemphigus indication.
-
Clinical Program Expansion Underway
Phase 1b studies are active in Australia, the U.S., New Zealand, Czech Republic, and Japan, with proof-of-concept basket studies planned for additional autoimmune indications.
-
Registrational Studies Expected in 2027
Gamgertamig is currently in Phase 2 studies and is expected to enter registrational studies in 2027, with the pemphigus designation supporting that pathway.
Analysis · LKFT · Life Sciences
The FDA's Orphan Drug Designation for gamgertamig in pemphigus adds a third autoimmune indication to the drug's regulatory profile, following prior designations in AIHA and ITP. Orphan status confers seven years of U.S. market exclusivity upon approval, plus tax credits and fee waivers — meaningful commercial protection for a program Lakefront is developing with Gilead. The designation also validates the expansion strategy into pemphigus vulgaris and foliaceus, both of which are already enrolling in the Phase 1b seropositive autoimmune study. With registrational studies expected in 2027, this milestone de-risks the pemphigus indication specifically and reinforces the broader BCMAxCD3 platform thesis.
How filings like this one have moved
In the 30 days to Aug 25, 2026, 29.6% of the 2856 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.04%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LKFT was trading at $29.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $25.68 to $37.78. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.